NEW YORK (GenomeWeb) – A tumultuous April for Cancer Genetics brought a lawsuit from investors, the disclosure of accounts receivables problems in its clinical services business, and the US Food and Drug Administration clearance for a test that it expects to see broad adoption.

Most important, according to its interim CEO John Roberts, the company has embarked on a plan to transform the company to put it on a path to profitability.  

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.